The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie...
-
Upload
cameron-vaughan -
Category
Documents
-
view
215 -
download
0
Transcript of The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie...
![Page 1: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/1.jpg)
The Therapeutic Use of Reclast® (zoledronic acid) in Paget’s Disease
of the BoneStephanie Piemontese
PharmD Candidate 2010University of Pittsburgh School of
Pharmacy
![Page 2: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/2.jpg)
Objectives
![Page 3: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/3.jpg)
Normal Bone Physiology
• Bone has both structural and metabolic properties– Structural: locomotion, respiration, and protection– Metabolic: storage of Ca++, Phos, and carbonate; H
ion buffering, bind toxins and heavy metals• Bone is made up of collagen and mineral
components– Collagen gives flexibility and energy-absorbing
capability– Mineral component gives stiffness and strength
![Page 4: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/4.jpg)
• Two types of bone: cortical and trabecullar– Cortical bone’s major function
strength/protection– Trabecular bone is more metabolically active
• fjfj
![Page 5: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/5.jpg)
Paget’s Disease of the Bone
• Non malignant disease involving accelerated bone resorption followed by deposition of dense, chaotic, and ineffectively mineralized bone
• Differs from osteoporosis by the involvement of discrete sections of bone remodeling
• Schneider, Dipiro
![Page 6: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/6.jpg)
• Aside from osteoporosis Paget’s is the most common bone disorder
• Equally prevalent in men and women• Increased incidence in persons > 50 yo• 3% US population affected• Schneider
![Page 7: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/7.jpg)
Clinical Features Schneid, Dum
• Can affect any area• Most commonly involves axial skeleto– Usually affects at least 2 bones
• Can be symptomatic of asymptomatic• Most common symptom is pain the affected
bone
![Page 8: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/8.jpg)
schn
• Complications include: Neurologic, hearing, vision, cardiac, and oncologic
![Page 9: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/9.jpg)
• Occurs in 3 phases (Schneider)1. Intense osteoclastic activity and bone resorption2. Osteoblastic phase producing woven bone, with
ineffective mineralization3. Dense cortical and trabecullar bone deposition
![Page 10: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/10.jpg)
Etiology schle, dum
• Viral and hereditary causes• Particles contained in osteoclasts of Pagetic
bone appear to be paramyxovirus nucleocapsids
![Page 11: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/11.jpg)
Summary
![Page 12: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/12.jpg)
Reclast® (zoledronic acid)
• Approved by the FDA in 2001• A bisphosphonate approved for:– Treatment of osteoporosis in postmenopausal women– Prevention of osteoporosis in postmenopausal
women – Treatment to increase bone mass in men with
osteoporosis– Treatment and prevention of glucocorticoid-induced
osteoporosis in patients expected to be on glucocorticoids for at least 12 months
![Page 13: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/13.jpg)
Indication for Paget’s Disease
• Indicated for treatment of Paget’s disease in both men and women
• Indicated in patients with elevations in serum alkaline phosphatatse of > 2 times higher than upper limit of age-specific normal rangesOR
• Those who are symptomatic OR
• Those at risk for complications from their disease
![Page 14: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/14.jpg)
Dosage and Administration• A single 5mg infusion given IV over no less than 15
minutes• 1500mg elemental calcium and 800 IU vitamin D daily• Administer through a separate vented infusion line• Avoid contact with any calcium or divalent cation-
containing solutions• Patients must be appropriately hydrated prior to
administration• Acetaminophen administration following Reclast
administration may reduce incidenc of acute-phase reaction symptoms
![Page 15: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/15.jpg)
Retreatment of Paget’s Disease
• After a single treatment with Reclast and extended remission period is observed
• Specific re-treatment data are not available• However, can be considered in patients who have
relapsed based on serum alkaline phosphataseOR
• In those patients who failed to achieve normalization of their serum alkaline phosphatase levelOR
• In symptomatic patients as dictated by medical practice
![Page 16: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/16.jpg)
Mechanism of Action
• Class: bisphosphonate• Acts primarily on the bone• Inhibitor of osteoclast-mediated bone
resorption• High affinity for mineralized bone
![Page 17: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/17.jpg)
Contraindications
• Hypcalcemia• Hypersensitivity to any component
![Page 18: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/18.jpg)
Warnings and Precautions
• Reclast® ≠ Zometa®• Hypocalcemia and Mineral Metabolism• Renal Impairment• Osteonecrosis of the Jaw (ONJ)• Pregnancy• Musculoskeletal Pain• Patients with Asthma
![Page 19: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/19.jpg)
Adverse Reactions
• Most common ADR (>10%) were pyrexia, myalgia, headache, arthralgia, pain in extermities
• Other clincially important ADR were flu-like illness, nausea, vomiting, diarrhea, eye inflammation, hypocalcemia, hypophosphatemia, ONJ, acute renal impairment, allergic reactions
![Page 20: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/20.jpg)
Drug Interactions
• Aminoglycosides• Loop diuretics• Nephrotoxic drugs• Drugs primarily excreted by the kidney
![Page 21: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/21.jpg)
Use in Specific Populations
• Pregnant and nursing mothers – should not receive Reclast
• Pediatric use – not indicated• Geriatric use – monitor renal function• Renal Impairment – should not be used
<35mL/min• Hepatic Impairment – no data
![Page 22: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/22.jpg)
Pharmacodynamics
• Treatment with a 5mg annual dose of Reclast reduces bone turnover markers to the pre-menopausal range with an approxiamte 55% reduction
• Serum beta-C-telopeptides = bone resorption• Bone specific alkaline phosphatase & serum N-
terminal propeptide of type I collagen = bone formation
• Progressive reduction of bone turnover with repeated annual dosing
![Page 23: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/23.jpg)
Pharmacokinetics
• Distribution– Triphasic process– t/2α=0.24hrs, t1/2β=1.87hrs, t1/2γ=146hrs– Protein binding ranges from 28% to 53%
• Metabolism– Does not inhibit P450 enzymes in vitro
• Elimination
![Page 24: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/24.jpg)
Clinical Trial
• Reid IR, Miller P, Lyles K, et al. Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget’s Disease. NEJM. 2005; 353:898-908.
![Page 25: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/25.jpg)
Methods
• Two randomized, controlled trials– independent of each other– identical protocols
• Included patients from N. America, Europe, Australia, S. Africa
• Pooled results in a joint analysis
![Page 26: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/26.jpg)
Patient Selection
Inclusion Criteria• Men and women > 30yo• Radiologically confirmed
Paget’s disease• Alkaline phosphatase level >
2x upper limit of normal
Exclusion Criteria• Serum 25-hydroxyvitamin D
level < 15ng/mL• Primary hyperparathyroidism• Evidence of hepatic/renal
disease• History of uveitis, iritis, or
upper GI disorders• Diabetic
nephropathy/retinopathy• Use of therapy specific to
Paget’s disease in the preceding 180 days
![Page 27: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/27.jpg)
Randomization and Treatment
• Double-blind random assignment through an interactive voice-response system to receive:• A 5mg infusion of zoledronic acid over 15 minutes
followed by placebo tablets for 60 daysOR
• A saline infusion followed by a 30mg of risedronate per day for 60days
• All patients received 1g calcium and 400-1000 U calciferol per day
![Page 28: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/28.jpg)
Primary Study Endpoints
• Proportion of patients who had a therapeutic response– Normalization of or reduction of at least 75% in
alkaline phosphatase excess at 6 months
• Measurements were made by Covance Central Laboratory Services
![Page 29: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/29.jpg)
Secondary Study Endpoints
• Biochemical markers of bone resorption and bone formation
• QOL measured by Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36)
• Bone histomorphometry• Safety assessments
![Page 30: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/30.jpg)
Statistical Analyses
• Each study had a power of 80% to demonstrate noninferiority of zoledronic acid relative to risedronate
• Assumed a dropout rate of ~10% per study• Calculated would need 88 patients in each
group (176 total)
![Page 31: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/31.jpg)
Results
• 182 patients enrolled in zoledronic acid group• 175 patients in the risedronate group
• Similar baseline characteristics– favored male gender in the overall study
population
![Page 32: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/32.jpg)
Serum Alkaline Phosphatase
![Page 33: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/33.jpg)
Serum N-terminal propeptide of type I collagen
![Page 34: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/34.jpg)
Serum βC-telopeptide of type I collagen
![Page 35: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/35.jpg)
Urinary αC-telopeptide of type I collage to creatine ratio
![Page 36: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/36.jpg)
QoL Assessment
Component of SF-36 % patients -Zoledronic Acid % patients -Risedronate
Physical Functioning 43 34
Physical Role 28 26
Bodily Pain 50 37
General Health 39 31
Vitality 49 40
Social Functioning 28 28
Emotional Role 23 16
Mental Health 28 27
Percent of Patients with at least 5-point change at 6 months
![Page 37: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/37.jpg)
Mean changes from baseline in the 8 domains assessed by the SF-36
![Page 38: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/38.jpg)
Bone Biopsy
• Performed in 22 patients– 12 zoledronic acid patients, 10 risedronate
patients
• 2 specimens (1 from each group) came from sites of Paget’s disease
• Both were otherwise normal– Increased mineralization in the risedronate
specimen
![Page 39: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/39.jpg)
Adverse Events
• No deaths occurred• 146 ADE in zoledronic acid group– 9 serious ADE
• 133 ADE in risedronate group– 11 serious ADE
• Marked clustering of ADE in first 3 days after IV drug administration– 53.7% zoledronic acid patients vs. 25.0%
risedronate patients (p <0.01)
![Page 40: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/40.jpg)
ADE Days 1-3Variable # patients in
Zoledronic Acid (%)N=177
# patients in Risedronate (%)N=172
P value
Influenza-like illness 17 (9.6) 7 (4.1) 0.06
Myalgia 13 (7.3) 6 (3.5) 0.16
Pyrexia 13(7.3) 1 (0.6) <0.01
Fatigue 12 (6.8) 4 (2.3) 0.07
Headache 12 (6.8) 7 (4.1) 0.35
Rigors 12 (6.8) 1 (0.6) <0.01
Nausea 11 (6.2) 3 (1.7) 0.05
Bone pain 9 (5.1) 2 (1.2) 0.06
![Page 41: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/41.jpg)
• Frequencies of GI and renal or urinary disorders were similar
• 1 patient in each group with preexisting renal impairment had moderate increases in SCr
• Mean SCr level decreased slightly but significantly in the zoledronic acid group vs. the risedronate group by day 10
• Hypocalcemia – decreases in serum Ca++ levels in both groups at day 10
![Page 42: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/42.jpg)
Trial Extension
• Patients who met therapeutic response• Serum alkaline phosphatase measured at 6-
month intervals• Median 190 days after end of core study
period– 21/82 risedronate patients lost therapeutic
response– 1/113 zoledronic acid patients lost therapeutic
response
![Page 43: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/43.jpg)
Weaknesses
• Raw values for many statistics not reported
![Page 44: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/44.jpg)
Reclast’s place in Paget’s Disease Therapy
![Page 45: The Therapeutic Use of Reclast® (zoledronic acid) in Pagets Disease of the Bone Stephanie Piemontese PharmD Candidate 2010 University of Pittsburgh School.](https://reader036.fdocuments.net/reader036/viewer/2022070305/5514368f550346ec488b622c/html5/thumbnails/45.jpg)
Questions